Kiora Pharmaceuticals, Inc.KPRX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · kiorapharma.com
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. Its lead candidate KIO-301 is a molecular photoswitch designed to restore light sensitivity to retinal ganglion cells, initially for retinitis pigmentosa.
Key ratios
FCF / Sales
53.4%2024
Net margin
22.4%TTM
2024
22.4%
ROA
-21.9%TTM
2025
-19.5%2024
13.9%2023
-33.5%
ROE
-56.4%TTM
2025
-51.7%2024
22.6%2023
-142.9%
Recent news
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Track KPRX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer